Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed

NCT06547476 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Tucidinostat (chidamide), PD-1 inhibitor (tislelizumab), anlotinib

Sponsor

Guangdong Provincial People's Hospital